Nuveen
KRSA

Nuveen’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Nuveen’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-656
Closed -$1.11M – 3247
2019
Q3 		$1.11M Sell
656
-180
-22% -$38.9K ﹤0.01% 2655
2019
Q2 		$1.34M Buy
+836
New +$237K ﹤0.01% 2620

Other funds holding KRSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $146M AUM 71.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's KRSA Position: Q4 2019 in Review

Nuveen sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2019, closing a stake of 656 shares — an estimated $1.11M sold.

Nuveen first reported a position in KRSA in Q2 2019 and held it in 2 quarters. The position peaked at $1.34M in Q2 2019. 73 funds tracked by Wall St. Rank hold KRSA as of Q4 2019.

  • Nuveen reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Nuveen sold 656 Korsana Biosciences, Inc. Common Stock shares in Q4 2019, an estimated $1.11M.
  • Nuveen first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Nuveen's Korsana Biosciences, Inc. Common Stock position peaked at $1.34M in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2019.

Based on Nuveen's 13F filing for Q4 2019, filed 14 Feb 2020.